Research sets global standard for Crohn’s treatment
Trial results published by Cambridge researchers earlier this year and involving patients at Addenbrooke’s Hospital are helping to set new global standards for the treatment of Crohn’s disease, it has emerged.
Experts leading on the PROFILE trial say that following a blaze of publicity about their ground-breaking research, clinicians across the globe are making changes in the way they provide care to patients newly diagnosed with Crohn’s disease.
Crohn’s disease is a life-long condition characterised by inflammation of the digestive tract and affects around one in 350 people in the UK. Moderate and severe presentations of Crohn’s disease can impact greatly on quality of life with symptoms like stomach pain, diarrhoea, weight loss and fatigue.
Professor Miles Parkes
PROFILE was the earliest “early treatment” clinical trial ever conducted for patients with a new diagnosis of Crohn’s disease and was led by chief investigator, Professor Miles Parkes, of the National Institute for Health and Care Research Cambridge Biomedical Research Centre at Addenbrooke’s.
The PROFILE trial was sponsored by Cambridge University Hospitals (CUH) NHS Foundation Trust, which runs Addenbrooke’s and the Rosie hospitals, and the University of Cambridge.
It recruited from 40 hospitals across the UK and was supported by the National Institute for Health and Care Research (NIHR) Clinical Research Network.
PROFILE involved 386 newly-diagnosed patients from 40 hospitals who were assigned at random to one of two treatment groups. Each group was given a different treatment strategy, and patients were followed up over the course of a year.
For full article visit: CUH News
Latest from CCTU
Targeting the immune system could prevent future heart attacks, Cambridge-led trial suggests
Cambridge researchers have discovered that an existing therapy which boosts protective immune cells in people who have recently had heart attacks reduces…
Cambridge study finds hot flush treatment has anti-breast cancer activity
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast…
Innovative trial offers hope on World Pancreatic Cancer Day
An early-stage trial, recently opened at Addenbrooke's Hospital, offers new hope to people with late-stage pancreatic cancer and their families.
…
